Andere Sprachen Neurocrine Biosciences, Inc. Deutsche Boerse AG

Aktien

900964

US64125C1099

NB3

Markt geschlossen - Deutsche Boerse AG Andere Börsenplätze 08:02:51 07.06.2024			% 5 Tage	% 1. Jan.
121.6 ^EUR	-0.37%		-1.93%	+2.36%

05.06.	Transcript : Neurocrine Biosciences, Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 02:30 PM
03.06.	Neurocrine Biosciences, Inc. gibt die Veröffentlichung der Ergebnisse der primären CAHtalyst-Studie der Phase 3 mit Crinecerfont zur Behandlung von CAH im New England Journal of Medicine bekannt	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Groundbreaking Study by MAIA Biotechnology (NYSE: MAIA) Indicates Promising New Treatment for Advanced Lung Cancer	06.06.
Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024	03.06.
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	03.06.
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	03.06.
Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	03.06.
Neurocrine Biosciences, Inc. Announces Publication of Primary CAHtalyst Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine	03.06.
Neurocrine Biosciences Insider Sold Shares Worth $5,338,565, According to a Recent SEC Filing	31.05.
Neurocrine Biosciences to Participate at Investor Conferences in June	29.05.
Neurocrine Biosciences to Present New Phase 3 CAHtalyst Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024	29.05.
Neurocrine Biosciences Says CEO Kevin Gorman Retiring	28.05.
Neurocrine founder-CEO Gorman to retire in October	28.05.
Neurocrine CEO set to retire	28.05.
Neurocrine Biosciences Announces CEO Succession Plan	28.05.
Neurocrine Biosciences, Inc. Announces Dr. Kyle Gano as Director, Effective October 11, 2024	28.05.
Neurocrine Biosciences Announces CEO Changes	28.05.
Neurocrine Biosciences to Present New Phase 3 CAHtalyst™ Data in Adult and Pediatric Patients with CAH and Study Data for Modified-Release Hydrocortisone in Primary Adrenal Insufficiency and CAH at ENDO 2024	28.05.
Neurocrine Biosciences Insider Sold Shares Worth $297,860, According to a Recent SEC Filing	21.05.
Neurocrine Biosciences Announces Publication of Phase 3 KINECT®-4 Post Hoc Analysis Demonstrating Clinically Meaningful and Sustained Improvement in Tardive Dyskinesia With Long-Term Use of INGREZZA® (valbenazine) Capsules	21.05.
Neurocrine Biosciences, Inc. Announces Publication of Phase 3 KINECT-4 Post Hoc Analysis	21.05.
Encephalopathy Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)	21.05.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Neurocrine Biosciences, Inc. Deutsche Boerse AG

Aktien

900964

US64125C1099

NB3

Andere Sprachen

Filter